CARsgen Therapeutics Holdings Limited (HKG:2171)
Hong Kong
· Delayed Price · Currency is HKD 21.80
-0.96 (-4.22%)
Apr 29, 2026, 4:08 PM HKT
HKG:2171 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2019 |
|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 2020 - 2019 |
| Revenue | 125.66 | 39.43 | - | - | 25.81 | Upgrade
|
| Revenue Growth (YoY) | 218.74% | - | - | - | - | Upgrade
|
| Cost of Revenue | 45.71 | 24.68 | - | - | - | Upgrade
|
| Gross Profit | 79.95 | 14.75 | - | - | 25.81 | Upgrade
|
| Selling, General & Admin | 71.81 | 162.84 | 133.31 | 136.61 | 126.52 | Upgrade
|
| Research & Development | 243.38 | 463.74 | 660.04 | 679.49 | 501.03 | Upgrade
|
| Other Operating Expenses | -7.35 | -49.62 | -8.3 | -10.45 | -14.34 | Upgrade
|
| Operating Expenses | 307.84 | 576.97 | 785.05 | 805.65 | 613.21 | Upgrade
|
| Operating Income | -227.9 | -562.22 | -785.05 | -805.65 | -587.4 | Upgrade
|
| Interest Expense | -6.9 | -5.71 | -4.66 | -15.52 | -10.87 | Upgrade
|
| Interest & Investment Income | 14.81 | 41.92 | 72.79 | 27.57 | 9.61 | Upgrade
|
| Currency Exchange Gain (Loss) | 121.5 | -82.24 | -30.47 | -97.35 | 7.45 | Upgrade
|
| Other Non Operating Income (Expenses) | - | - | - | - | -4,156 | Upgrade
|
| EBT Excluding Unusual Items | -98.49 | -608.26 | -747.39 | -890.95 | -4,737 | Upgrade
|
| Gain (Loss) on Sale of Assets | -4.42 | -0.45 | - | - | - | Upgrade
|
| Asset Writedown | - | -189.08 | - | - | - | Upgrade
|
| Pretax Income | -102.91 | -797.79 | -747.39 | -890.95 | -4,737 | Upgrade
|
| Income Tax Expense | - | 0.35 | 0.41 | 1.3 | 7.65 | Upgrade
|
| Earnings From Continuing Operations | -102.91 | -798.13 | -747.79 | -892.25 | -4,744 | Upgrade
|
| Minority Interest in Earnings | 5.05 | - | - | - | - | Upgrade
|
| Net Income | -97.86 | -798.13 | -747.79 | -892.25 | -4,744 | Upgrade
|
| Net Income to Common | -97.86 | -798.13 | -747.79 | -892.25 | -4,744 | Upgrade
|
| Shares Outstanding (Basic) | 552 | 553 | 556 | 552 | 387 | Upgrade
|
| Shares Outstanding (Diluted) | 552 | 553 | 556 | 552 | 387 | Upgrade
|
| Shares Change (YoY) | -0.15% | -0.58% | 0.82% | 42.60% | 95.23% | Upgrade
|
| EPS (Basic) | -0.18 | -1.44 | -1.34 | -1.62 | -12.26 | Upgrade
|
| EPS (Diluted) | -0.18 | -1.44 | -1.34 | -1.62 | -12.26 | Upgrade
|
| Free Cash Flow | -242.03 | -427.69 | -463.77 | -778.45 | -688.16 | Upgrade
|
| Free Cash Flow Per Share | -0.44 | -0.77 | -0.83 | -1.41 | -1.78 | Upgrade
|
| Gross Margin | 63.62% | 37.41% | - | - | 100.00% | Upgrade
|
| Operating Margin | -181.36% | -1426.04% | - | - | -2275.59% | Upgrade
|
| Profit Margin | -77.88% | -2024.43% | - | - | -18379.97% | Upgrade
|
| Free Cash Flow Margin | -192.60% | -1084.81% | - | - | -2665.95% | Upgrade
|
| EBITDA | -203.91 | -497.08 | -717.64 | -748.73 | -552.49 | Upgrade
|
| EBITDA Margin | -162.26% | - | - | - | - | Upgrade
|
| D&A For EBITDA | 23.99 | 65.14 | 67.41 | 56.92 | 34.91 | Upgrade
|
| EBIT | -227.9 | -562.22 | -785.05 | -805.65 | -587.4 | Upgrade
|
| EBIT Margin | -181.36% | - | - | - | - | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.